News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forest Laboratories, Inc. (FRX) Announces Intention To Continue Marketing Both NAMENDA® TABLETS And Once-Daily NAMENDA XR® Into The Fall Of 2014


6/11/2014 8:15:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company, today announced that it intends to continue to market both its NAMENDA® (memantine HCl) 5 mg and 10 mg tablets and once-daily NAMENDA XR® (memantine HCl) extended-release capsules into the fall of 2014. The Company noted that patient and caregiver response to the NAMENDA XR® product has been exceptionally positive, with caregivers and physicians clearly recognizing the benefits of the single daily dosing regimen. Forest stated that its decision to defer final conversion to the NAMENDA XR® product later in the year will not affect the company’s ability to meet its financial objectives for the product.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES